Edgar Filing: JOHNSON & JOHNSON - Form 8-K

JOHNSON & JOHNSON Form 8-K June 30, 2014

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549

FORM 8-K

CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of report (Date of earliest event reported): June 30, 2014

(Exact name of registrant as specified in its charter)

I-3215 22-1024240 New Jersey

(State or Other Jurisdiction of (Commission File Number)

(IRS Employer Identification No.) Incorporation)

One Johnson & Johnson Plaza, New Brunswick, New Jersey 08933

(Address of Principal Executive Offices) (Zip Code)

Registrant's telephone number, including area code: 732-524-0400

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) 0
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Edgar Filing: JOHNSON & JOHNSON - Form 8-K

Item 8.01. Other Events

On June 30, 2014, the Registrant announced that it has completed the divestiture of its Ortho-Clinical Diagnostics business to The Carlyle Group for approximately \$4 billion, subject to customary adjustments. Under the terms of the transaction, The Carlyle Group has acquired the Ortho-Clinical Diagnostics business, a global provider of solutions for screening, diagnosing, monitoring and confirming diseases. The Ortho-Clinical Diagnostics business generated net sales of approximately \$1.9 billion in 2013.

The Registrant will discuss the financial impact of this divestiture during its scheduled quarterly earnings call on July 15, 2014.

The related press release dated June 30, 2014 is attached as Exhibit 99.1 to this Report.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No. Description

99.1 Press Release dated June 30, 2014

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Johnson & Johnson (Registrant)

By: /s/ Lacey P. Elberg

Lacey P. Elberg
Assistant Secretary

June 30, 2014